Tyrogenex has developed X-82, an orally administered, dual VEGFR/PDGFR inhibitor, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study shows that X-82 is well tolerated, does not exhibit any dose-limiting toxicity and demonstrates preliminary signs of anti-tumor activity. The company has initiated phase 2 studies of X-82 for both wet AMD and solid tumors in 2015.
Looking for a particular Tyrogenex employee's phone or email?
Tyrogenex Questions
The Tyrogenex annual revenue was $1.6 million in 2026.
Tyrogenex is based in Rockville, Maryland.
The NAICS codes for Tyrogenex are [54, 541, 325, 32, 3254].
The SIC codes for Tyrogenex are [873, 28, 283, 87].
Related Companies
